CHICAGO TRUST Co NA Has $11.91 Million Stake in AbbVie Inc. $ABBV

CHICAGO TRUST Co NA decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,777 shares of the company’s stock after selling 2,153 shares during the period. AbbVie makes up approximately 1.9% of CHICAGO TRUST Co NA’s investment portfolio, making the stock its 9th biggest position. CHICAGO TRUST Co NA’s holdings in AbbVie were worth $11,913,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Cassia Capital Partners LLC lifted its position in shares of AbbVie by 4.8% in the first quarter. Cassia Capital Partners LLC now owns 6,954 shares of the company’s stock worth $1,513,000 after buying an additional 318 shares in the last quarter. Fulton Bank N.A. grew its holdings in AbbVie by 3.2% during the 1st quarter. Fulton Bank N.A. now owns 48,582 shares of the company’s stock valued at $10,566,000 after buying an additional 1,496 shares in the last quarter. Secured Retirement Advisors LLC increased its stake in AbbVie by 5.3% in the 1st quarter. Secured Retirement Advisors LLC now owns 1,775 shares of the company’s stock worth $386,000 after acquiring an additional 90 shares during the last quarter. Whelan Financial increased its stake in AbbVie by 4.3% in the 1st quarter. Whelan Financial now owns 1,788 shares of the company’s stock worth $389,000 after acquiring an additional 73 shares during the last quarter. Finally, Lederer & Associates Investment Counsel CA raised its holdings in shares of AbbVie by 0.5% during the 1st quarter. Lederer & Associates Investment Counsel CA now owns 10,808 shares of the company’s stock worth $2,351,000 after acquiring an additional 53 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

Shares of AbbVie stock opened at $251.07 on Thursday. The stock has a market cap of $443.59 billion, a price-to-earnings ratio of 123.68, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32. The stock has a 50 day moving average price of $217.86 and a 200-day moving average price of $219.76. AbbVie Inc. has a one year low of $184.63 and a one year high of $255.99.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. Sell-side analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is currently 340.89%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Canaccord Genuity Group increased their target price on AbbVie from $265.00 to $273.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Guggenheim reiterated a “buy” rating and set a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Piper Sandler reissued an “overweight” rating and issued a $298.00 price objective on shares of AbbVie in a research note on Tuesday, June 23rd. Finally, Morgan Stanley boosted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $253.81.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.